Organic Active Ingredients TRIZ Cases

Combines ethyl eicosapentanoate with estrogen or progesterone to treat non-alcoholic steatohepatitis.

Chelating agents bind metal ions to prevent catalytic degradation of avenanthramides, maintaining antioxidant activity without discoloration.

Formula Ib compounds with specific substituents enhance NLRP3 binding affinity to reduce inflammatory cytokine release.

Serotonin derivatives replace toxic injectable chelators by enabling oral administration for safer iron overload management.

An MTA-uncompetitive compound binds the MTA-PRMT5 complex to achieve selective enzyme inhibition.

Novel aminoalkylbenzothiazepine derivative inhibits bile acid resorption to promote large intestine water secretion.

Scopolin maintains bone density by stimulating osteoblast differentiation and inhibiting resorption markers, addressing postmenopausal osteoporosis.

Targeting NADH-quinone oxidoreductase activity lowers reactive oxygen species levels to treat oxidative stress.

Combines five antimicrobials into a unified protocol to resolve the contradiction between treatment simplicity and efficacy reliability.

A diagnostic method assesses CES2 expression levels in tumor tissues to determine patient susceptibility to ester-prodrug therapy.

Morpholine derivative salts form crystalline structures to resolve poor water solubility and oxidation instability of the free base.

Artificial nucleic acid cassettes assemble virus-like particles to induce robust immune responses while ensuring safety for vulnerable populations.

Optimized excipient ratios in solid S-pindolol formulations resolve storage stability versus dissolution trade-offs.

Liposome composition encapsulates gemcitabine in a dissolved state within an inner water phase for simultaneous administration with immune checkpoint inhibitors.

Novel bifunctional compounds recruit ubiquitin ligase to degrade BTK without triggering IMiD toxicity, enabling higher doses and prolonged treatment.

Anti-CD25 antibody-drug conjugates paired with secondary agents treat mixed CD25+ and CD25- tumor populations while reducing normal cell toxicity.

Formula I macrocyclic compounds inhibit MCL-1 protein activity to treat malignant cell survival.

Characterizing triclinic crystalline form 1 of 5-MeO-DPT fumarate resolves solid-state complexity while improving storage stability and bioavailability.

Segmented microsphere populations resolve burst release trade-offs while maintaining therapeutic levels.

Segmenting rapid-absorption powder from sustained-release chewing gum resolves the trade-off between initial absorption speed and user-controlled duration.

Star-shaped peptide polymers disrupt bacterial membrane integrity, overcoming intrinsic resistance mechanisms in Gram-negative pathogens.

A two-component system mixes acetylsalicylic acid with carbonic acid salt to form an immediate aqueous solution.

Small molecule cocktail converts glial cells into functional neurons in situ, avoiding immunorejection and tumorigenesis risks from cell transplantation.

Thiazolidinedione analogs modulate the mitochondrial pyruvate carrier to treat non-alcoholic fatty liver disease.

Functionalized butylamide linkers in 4-phenylpiperazine derivatives enhance dopamine D3 receptor affinity and water solubility.

Trifluoroacetic acid and glycol suppress acid-catalyzed conversion of 8-hydroxyoxymorphone to genotoxic 14-hydroxymorphinone during hydrogenation.

A lyophilized polymeric wafer utilizes a composite matrix of hydroxypropyl cellulose and maltodextrin to achieve ultra-fast disintegration in aqueous media.

Bicyclic heterocyclic compounds inhibit FGFR4 activity to treat cancers resistant to existing therapies.

Structural modifications reduce broad-spectrum cytotoxicity while maintaining anti-tumor activity.

A novel rapamycin analogue increases oral bioavailability through structural modification.

Adeno-associated viral vectors deliver small interfering RNA to silence mutant SOD1 gene expression in motor neurons.

Substituted 1-benzylquinoxalin-2(1H)-one analogs act as positive allosteric modulators of the muscarinic acetylcholine receptor M1.

A preservative-free ophthalmic solution combines bimatoprost and timolol with sodium phosphate dibasic heptahydrate, citric acid monohydrate, and sodium chloride.

A wearable device monitors vital signs to detect opioid overdose conditions.

Inhaled nebivolol and flecainide convert atrial arrhythmia to normal sinus rhythm via pulmonary delivery.

Segmented metformin granules with swellable polymers control drug release rates, preventing gastrointestinal disorders caused by rapid absorption.

Ulvan-based viscosupplements resist hyaluronidase degradation, extending therapeutic duration and reducing injection frequency for arthritis treatment.

Dantrolene modulates calcium signaling to enhance GCase activity in neuronopathic Gaucher disease models.

Modular C2c1 expression constructs enable mammalian genome editing, resolving the contradiction between high precision and broad application scope.

A multi-component pharmaceutical composition targets oxidative stress and reperfusion injury in brain ischemia.

A chimeric polypeptide combines endonuclease and exonuclease activities to degrade specific nucleic acids in cancer cells.

Aza-pyridone compounds inhibit influenza viral replication by targeting the PA subunit endonuclease, overcoming resistance to existing neuraminidase inhibitors.

Novel anthelmintic compounds resolve efficacy and bioavailability limitations by offering broad-spectrum coverage against internal and external parasites.

Anhydrous vapendavir free base crystals resolve phase transformation issues while maintaining solubility for picornavirus treatments.

Segmented aptamers target conserved poly-A domains to overcome steric hindrance and improve binding specificity.

Novel heterocyclic amides target the influenza nucleoprotein to overcome widespread resistance against existing neuramidase inhibitors.

Ethanol in lyophilized phenobarbital sodium inhibits hydrolysis, reducing impurities below 0.2% while avoiding benzyl alcohol toxicity risks.